7.25 Biologic DMARDs & Immunologic Therapies – Detailed Study Notes

Biological Disease-Modifying Anti-Rheumatic Drugs (Biologic DMARDs)

• Focus: Large-molecule, protein-based agents that modulate immune pathways in rheumatoid arthritis (RA) and other inflammatory disorders.
• Contrast with small-molecule “synthetic” DMARDs previously studied (e.g., methotrexate, JAK inhibitors).

Why These Agents Are “Biologic”

• Derived from living cells (recombinant DNA, hybridoma, etc.).
• Large, complex proteins—usually monoclonal antibodies (mAbs) or fusion proteins.
• Orally unstable → almost always delivered parenterally (sub-Q, IV).
• Digestion risk if swallowed → destroyed by intestinal enzymes.

Cytokine-Driven Inflammation: The Therapeutic Targets

• Pro-inflammatory cytokines: \text{TNF-\alpha},\; \text{IL-1\beta},\; \text{IL-6},\; \text{IL-17A/F},\; \text{IL-23},\; \text{IFN-\gamma}.
• Anti-inflammatory cytokines: \text{IL-10},\; \text{TGF-\beta}.
• Excess of pro-inflammatory mediators ⇒ chronic synovial destruction, edema, systemic effects.

Naming & Nomenclature (Key for Exams)

• -mab / ‑mab ⇒ monoclonal antibody (full IgG).
• -cept ⇒ receptor fusion protein that “intercepts” ligand (decoy receptor).
• -nib ⇒ small-molecule kinase inhibitor (e.g., “–tinib” for JAK/TK inhibitors).
• Historical infix (no longer official):
 ◦ -xi- = chimeric (human + mouse).
 ◦ -zu- = humanized.
 ◦ -u- = fully human.

Two Core Biologic Strategies

1. Ligand Neutralization (“mop-up” strategy)
    • Full antibody binds soluble cytokine → ligand can’t reach its receptor.

2. Decoy Receptor / Receptor Blockade
    • Construct = extracellular domain of native receptor + IgG $\text{F}_\text{C}$ tail.
    • Binds cytokine with high affinity → prevents interaction with cell-surface receptor.
    • Sometimes antibody directly targets the receptor instead of the ligand.

TNF-α Inhibitors

Common class effects:
• Injection-site erythema, pain, fever, hypotension (infusion reactions).
• Immunosuppression → $\uparrow$ risk of serious infections (TB reactivation, fungal, opportunistic).
• Long-term: lymphomas, other malignancies.

IL-1 Blockade

Clinical pearls:
• Useful in RA, cryopyrin-associated periodic syndromes (CAPS), other autoinflammatory disorders.
• Anakinra often combined with anti-TNF if monotherapy insufficient.
• Generally lower opportunistic infection rates vs TNF-α inhibitors.

IL-17 / IL-23 / IL-12 Axis

TH17 cells secrete IL-17A/F; IL-23 maintains TH17 phenotype.

Exam cues:
• “–k(i)numab” often signals IL-17 or IL-23 pathway.
• Stelara unique dual targeting frequently tested.

IL-6 Blockers

• IL-6 signals via membrane IL-6R or soluble IL-6R + accessory GP130 ⇒ JAK/STAT cascade.
• Tocilizumab (Actemra): humanized IgG1 mAb vs IL-6R (soluble & membrane).
• Sarilumab: fully human mAb vs IL-6R (similar).
Uses: RA refractory to TNF blockade, giant-cell arteritis, cytokine-release syndrome.

Integrin Antagonist

• Vedolizumab (Entyvio): humanized mAb against integrin $\alpha4\beta7$.
 ◦ Blocks binding to MAdCAM-1 on GI endothelium → prevents leukocyte trafficking into gut mucosa.
 ◦ Indicated for ulcerative colitis & Crohn’s disease.
• Pathophysiology reminder: integrins mediate leukocyte “rolling → adhesion → transmigration” during inflammation.

Sphingosine-1-Phosphate (S1P) Receptor Modulators

• Example: Ozanimod (Zeposia).
• MOA: irreversible agonist at S1P₁ on T-cells → receptor internalization & degradation → T-cells trapped in lymph nodes (cannot egress to blood/tissue).
• Indications: multiple sclerosis, ulcerative colitis.
• Oral small molecule, but concept highlighted to contrast with injectable biologics.

Additional Interleukin Blockers for Atopic Dermatitis / Eczema

VEGF / Angiogenesis Inhibitors

• Excess VEGF drives tumor vascularization & wet age-related macular degeneration (AMD).

Clinical correlations: anti-VEGF therapy can cause impaired wound healing, hypertension, proteinuria.

Co-Stimulation Blocker: Abatacept (Orencia)

• Fusion protein: extracellular domain of CTLA-4 + IgG1 $F_C$.
• Binds CD80/CD86 on antigen-presenting cells → prevents interaction with CD28 on T-cells.
• Blocks second signal required for T-cell activation (first signal = $\text{TCR – MHC}$).
• Result: ↓ T-cell–mediated inflammation in RA, psoriatic arthritis, juvenile idiopathic arthritis.
• Exam alert: Abatacept does NOT block the T-cell receptor; it blocks co-stimulation.

Naming Tricks & Quick Recall Aids

• “SEPT” → interSEPTs cytokine (decoy receptor). Example: Etanercept, Rilonacept, Aflibercept.
• “MAB” → monoclonal antibody; source infixes (xi = chimeric, zu = humanized, u = fully human).
• “NIB” → small-molecule kinase inhibitor (e.g., Tofacitinib for JAK).
• IL-17 agents often end in –k(i)numab or contain -lumab; IL-23 p19 blockers end in -kizumab.

Common Adverse & Practical Considerations

• Injection/infusion reactions: fever, hypotension, flushing, erythema, pain.
• Immunosuppression ⇒ $\uparrow$ infections (TB screening prior to anti-TNF; monitor CBC, LFTs).
• Malignancy risk (lymphoma, skin cancers) with long-term cytokine blockade.
• Live vaccines contraindicated during therapy.
• Pregnancy: many biologics are $\text{IgG1}$ and cross placenta in 2nd/3rd trimester; weigh risks vs benefits.
• Cost & insurance authorization significant practical barrier; infusion center vs self-inject pens.

Links to Prior Courses & Real-World Relevance

• Immunology: reinforces concepts of antigen presentation, co-stimulation, cytokine signaling, Fc-mediated effector functions.
• Pharmacology: compares biologic vs small-molecule PK/PD, highlights importance of protein engineering (PEGylation, humanization).
• Pathology: connects cytokine excess to tissue damage in RA, psoriasis, IBD, cancers.
• Therapeutics: showcases personalized medicine—choice of pathway blockade guided by disease phenotype, comorbidities, prior response.

Ethical, Philosophical & Practical Implications

• Balancing immune suppression vs infection/cancer risk raises ethical prescribing dilemmas.
• High cost biologics challenge healthcare equity; biosimilars may alleviate but raise interchangeability debates.
• Animal-to-human chimeric antibodies illuminated immunogenicity concerns → propelled humanization technology.
• Blockade of normal physiologic signals (e.g., VEGF in wound healing, IL-17 in mucocutaneous immunity) requires vigilant adverse event monitoring.

Numerical / Statistical Nuggets

• Typical epitope size recognized by an antibody: $8\text{–}12$ amino acids.
• Injection-site reactions with Etanercept occur in $\approx 33\%$ of patients.
• Tocilizumab dosing (RA): $8\,\text{mg/kg}$ IV q4wk OR $162\,\text{mg}$ SC weekly/biweekly.
• Goal TNF-α trough inhibition: >90\% to correlate with clinical ACR20 response.

High-Yield Exam Checklist

✓ Distinguish ligand mop-up vs decoy receptor vs receptor-blocking mAbs.
✓ Memorize exemplar drugs per cytokine (TNF-α, IL-1, IL-6, IL-17, IL-23, VEGF).
✓ Recognize Etanercept, Rilonacept, Aflibercept as “-cept” fusion proteins.
✓ Abatacept blocks co-stimulation (CD80/86–CD28), not TCR.
✓ Stelara (Ustekinumab) = dual IL-12/23 blockade (p40).
✓ Integrin α4β7: Vedolizumab → gut-selective leukocyte blockade.
✓ S1P receptor modulators trap T-cells in lymph nodes (Ozanimod).
✓ Major class toxicity: infection, malignancy, injection reactions.